ID   MDA-MB-231 NAT1 down
AC   CVCL_A9BB
SY   NAT1 shRNA Clone 3; NAT1 Knockdown
DR   cancercelllines; CVCL_A9BB
DR   Wikidata; Q108820869
RX   PubMed=29315819;
RX   PubMed=29964355;
RX   PubMed=32555504;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Population: Caucasian.
CC   Characteristics: Transfected with a pcDNA5/FRT derived construct with a NATb promoter driving the expression of NAT1 (NATb/NAT1*4).
CC   Doubling time: 27.2 hours (PubMed=29315819).
CC   Knockout cell: Method=shRNA knockdown; HGNC; 7645; NAT1.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 7645; NAT1.
CC   Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0062 ! MDA-MB-231
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 05-10-23; Version: 7
//
RX   PubMed=29315819; DOI=10.1002/mc.22779;
RA   Stepp M.W., Doll M.A., Carlisle S.M., States J.C., Hein D.W.;
RT   "Genetic and small molecule inhibition of arylamine
RT   N-acetyltransferase 1 reduces anchorage-independent growth in human
RT   breast cancer cell line MDA-MB-231.";
RL   Mol. Carcinog. 57:549-558(2018).
//
RX   PubMed=29964355; DOI=10.1002/mc.22869;
RA   Carlisle S.M., Trainor P.J., Doll M.A., Stepp M.W., Klinge C.M.,
RA   Hein D.W.;
RT   "Knockout of human arylamine N-acetyltransferase 1 (NAT1) in
RT   MDA-MB-231 breast cancer cells leads to increased reserve capacity,
RT   maximum mitochondrial capacity, and glycolytic reserve capacity.";
RL   Mol. Carcinog. 57:1458-1466(2018).
//
RX   PubMed=32555504; DOI=10.1038/s41598-020-66863-4;
RA   Carlisle S.M., Trainor P.J., Hong K.U., Doll M.A., Hein D.W.;
RT   "CRISPR/Cas9 knockout of human arylamine N-acetyltransferase 1 in
RT   MDA-MB-231 breast cancer cells suggests a role in cellular
RT   metabolism.";
RL   Sci. Rep. 10:9804-9804(2020).
//